<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, July 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/4495780/gene-therapy-collaboration-and-licensing-deals?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=b49fjz&amp;utm_campaign=2308945+-+Gene+Therapy+Collaboration+and+Licensing+Deals+Report+2016-2026%3a+Gain+Visibility+into+Partner+Behaviour+and+Recurring+Deal+Structures&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Gene Therapy Collaboration and Licensing Deals 2016-2026">"Gene Therapy Collaboration and Licensing Deals 2016-2026"</a> has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive and structured analysis of 850+ gene therapy collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market. The definitive benchmark for gene therapy dealmaking Gene therapy partnering is driven by transformative, high-impact therapeutic approaches, with deal structures reflecting complex development pathways, manufacturing challenges, and significant long-term value potential. Establish a clear view of market standards The report enables a precise understanding of how gene therapy deals are structured in practice, allowing you to: <ul><li>Benchmark comparable transactions with confidence</li><li>Detailed analysis of upfronts, milestones, and royalty structures across relevant deals</li><li>Define realistic market parameters</li><li>Clear insight into how deal terms vary by therapy type, development stage, and partner profile</li><li>Support valuation and structuring decisions with evidence</li><li>Ground internal discussions in real transaction data rather than assumptions</li><li>Understand how leading companies approach dealmaking</li><li>Visibility into partner behaviour and recurring deal structures across a high-value and rapidly evolving therapeutic landscape</li><li>Full visibility into deal structure and execution</li></ul> Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice. This includes: <ul><li>Rights granted and retained</li><li>Development and commercialization responsibilities</li><li>Financial structures and payment triggers</li><li>Key contractual provisions and protections</li></ul> This level of transparency is critical to understanding how value, risk, and control are allocated within gene therapy partnerships, particularly in areas involving manufacturing scale-up, regulatory complexity, and long-term patient outcomes. Designed for real-world BD and strategy use The report is widely used to: <ul><li>Structure and benchmark advanced therapy transactions</li><li>Prepare for negotiations with well-defined market context</li><li>Evaluate licensing, co-development, and platform partnerships</li><li>Support internal strategy with robust, defensible data</li></ul> What's included? <ul><li>850+ gene therapy collaboration and licensing deals</li><li>Financial terms, including upfronts, milestones, and royalties where disclosed</li><li>Fully searchable deal directory (by company, therapy type, and development stage)</li><li>Direct access to SEC-filed agreements and source documents</li><li>Analysis of deal trends, key transactions, and active dealmakers</li><li>A trusted, evidence-based reference for gene therapy dealmaking</li></ul> Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how gene therapy partnerships are structured, negotiated, and valued. Companies Featured <ul><li>Abbvie</li><li>Acuitas Therapeutics</li><li>Adverum Biotechnologies</li><li>Affinia Therapeutics</li><li>AGC Biologics</li><li>Alexion Pharmaceuticals</li><li>Allogene Therapeutics</li><li>Alnylam Pharmaceuticals</li><li>Andelyn Biosciences</li><li>Arbor Biotechnologies</li><li>AstraZeneca</li><li>Beam Therapeutics</li><li>Biogen</li><li>BioMarin Pharmaceutical</li><li>Bluebird Bio</li><li>Boehringer Ingelheim</li><li>BridgeBio Pharma</li><li>Capsida Biotherapeutics</li><li>Carisma Therapeutics</li><li>Catalent</li><li>Charles River Laboratories</li><li>CRISPR Therapeutics</li><li>Cytiva</li><li>Denali Therapeutics</li><li>Dyno Therapeutics</li><li>Editas Medicine</li><li>ElevateBio</li><li>Eli Lilly</li><li>Forge Biologics</li><li>Genentech</li><li>Gilead Sciences</li><li>Intellia Therapeutics</li><li>Ionis Pharmaceuticals</li><li>Kite Pharma</li><li>Lonza</li><li>Mammoth Biosciences</li><li>Moderna</li><li>Novartis</li><li>Oxford BioMedica</li><li>Pfizer</li><li>Prime Medicine</li><li>Regeneron Pharmaceuticals</li><li>Rocket Pharmaceuticals</li><li>Sangamo Therapeutics</li><li>Sanofi</li><li>Sarepta Therapeutics</li><li>Spark Therapeutics</li><li>Thermo Fisher Scientific</li><li>Vertex Pharmaceuticals</li><li>Voyager Therapeutics</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/4495780/gene-therapy-collaboration-and-licensing-deals?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=b49fjz&amp;utm_campaign=2308945+-+Gene+Therapy+Collaboration+and+Licensing+Deals+Report+2016-2026%3a+Gain+Visibility+into+Partner+Behaviour+and+Recurring+Deal+Structures&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/6dj2wa</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YTU5ZTdlNTQtYzI1MC00ZTdjLWI4MjUtMDE2NzZlYTkxYjg3LTEwMjY3MzctMjAyNi0wNy0yMS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Gene Therapy Collaboration and Licensing Deals Report 2016-2026: Gain Visibility into Partner Behaviour and Recurring Deal Structures

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn